
    
      The purpose of the study is to evaluate the efficacy and safety of rh-prouk as
      pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed
      as a multicenter, active controlled, single blinded study. The primary endpoint is to assess
      percentage of patients achieve the coronary recanalization 90 minutes after thrombolysis. The
      secondary endpoint is to evaluate the mortality rate at day 30.
    
  